Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.47 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096856 | 0.89 | SCN9A (0.42) | SCN9A | |
| SCHEMBL6094409 | 0.75 | OPRL1 (0.37) | SCN9A | |
| Hydrochloric Acid SCHEMBL4423682 | 0.72 | EGFR (0.41) | SCN9A | |
| Hydrochloric Acid SCHEMBL4423689 | 0.72 | EGFR (0.41) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL3823598 | 0.71 | GNRHR (0.36) | SCN9AGNRHR | |
| Trifluoroacetic Acid SCHEMBL3819170 | 0.70 | GNRHR (0.36) | SCN9AGNRHRCRHR1 | |
| SCHEMBL4434100 | 0.70 | EGFR (0.37) | SCN9A | |
| Hydrochloric Acid SCHEMBL4434097 | 0.69 | EGFR (0.36) | SCN9A | |
| Hydrochloric Acid SCHEMBL4434105 | 0.69 | EGFR (0.36) | SCN9A | |
| SCHEMBL4434416 | 0.69 | PSEN1 (0.57) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | SCN9A 600/4885GNRHR 4641/4885CRHR1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.